Press Detail





Biotest AG:Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO), contract by five years

Biotest AG / Directorate change



Corporate-announcement transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO),
contract by five years

 
Dreieich, 21 March 2006. The Supervisory Board of Biotest AG, Dreieich,
extended the contract of Dr. Michael Ramroth (44), which was originally due
to expire in February 2007, by a further five years. Dr. Ramroth is
responsible for Finance and Central Services (including Legal and Human
Resources).

In his capacity as CFO, Dr. Ramroth has significantly improved the
financial situation of Biotest AG and established a solid foundation for
growth. The extension of his contract will ensure the continued confidence
of the company’s financial backers and shareholders.

About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulines, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In addition, Biotest also researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and blood cancer. The Diagnostic segment spans
reagents and serology and microbiology systems which are used, for example,
in blood transfusions. Biotest has around 1,100 employees worldwide and its
shares are listed in the Frankfurt Stock Exchange's Prime Standard.

Biotest AG: Tel. +49 6103 801-338
Fax: +49 6103 801-347, e-mail: investor_relations@biotest.de
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de

German Securities Code Number, ISIN ordinary shares: 522720, DE0005227201
German Securities Code Number, ISIN preferred shares: 522723, DE0005227235
Listed: Prime Standard/Official market
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart





DGAP 22.03.2006 
----------------------------------------------------------------------
 
language:     English
company:      Biotest AG
              Landsteinerstr. 5
              63303 Dreieich Deutschland
phone:        +49 - 6103 / 801 - 0
fax:          +49 - 6103 / 801 - 150
email:        mail@biotest.de
WWW:          www.biotest.de
ISIN:         DE0005227201, DE0005227235
WKN:          522720, 522723
indices:      
stockmarkets: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
              Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------